{"id":27682,"date":"2022-08-03T09:00:00","date_gmt":"2022-08-03T07:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-announces-results-from-phase-iii-resilient-trial-evaluating-onivyde-in-second-line-monotherapy-for-small-cell-lung-cancer\/"},"modified":"2024-07-22T12:28:23","modified_gmt":"2024-07-22T10:28:23","slug":"ipsen-announces-results-from-phase-iii-resilient-trial-evaluating-onivyde-in-second-line-monotherapy-for-small-cell-lung-cancer","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/press-releases\/ipsen-announces-results-from-phase-iii-resilient-trial-evaluating-onivyde-in-second-line-monotherapy-for-small-cell-lung-cancer\/","title":{"rendered":"Ipsen announces results from Phase III RESILIENT trial evaluating Onivyde\u00ae in second-line monotherapy for small cell lung cancer"},"content":{"rendered":"\n